Literature DB >> 10485436

Accelerated glutamine synthesis in critically ill patients cannot maintain normal intramuscular free glutamine concentration.

B Mittendorfer1, D C Gore, D N Herndon, R R Wolfe.   

Abstract

BACKGROUND: Muscle glutamine is severely depleted in critically ill patients (by approximately 50% to 80% of normal). Because muscle protein breakdown, and thus the release of glutamine from muscle protein, is enhanced in response to metabolic stress, the depletion of intramuscular glutamine could be due to its impaired synthesis or accelerated outward transport or both.
METHODS: To distinguish these possibilities, we measured skeletal muscle glutamine metabolism in five critically ill patients by means of primed, continuous infusions of 5-15N-glutamine and ring-2H5-phenylalanine and compared them to values we previously reported for healthy volunteers.
RESULTS: The intramuscular free glutamine concentration in patients was approximately 70% of that in healthy volunteers (5.8 +/- 0.6 mmol/L intracellular free water vs 21.5 +/- 2.8 mmol/L). Whole-body glutamine rate of appearance was 5.8 +/- 1.0 micromol x kg (-1) body wt x min (-1), and whole-body clearance was 19.3 +/- 3.3 mL x kg(-1) x min (-1). Despite the low intramuscular glutamine concentration in the patients, the rate of unidirectional outward transport from skeletal muscle into venous blood (1.1. +/- 0.2 micromol x 100 mL x leg(-1) x min(-1)) was similar to that observed in healthy volunteers (1.6 +/- 0.2 mol x 100 mL x leg(-1) x min(-1)); intramuscular synthesis was 2.7 +/- 0.9 micromol x 100 mL x leg(-1) x min(-1) compared with a normal value of 0.6 +/- 0.06 micromol x 100 mL x leg(-1) x min(-1). Net balance across the leg was normal.
CONCLUSIONS: The depletion of intramuscular glutamine in critically ill patients is not due to an impairment of the rate of synthesis. In fact, accelerated glutamine production cannot maintain normal intramuscular glutamine levels because of accelerated outward transport.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485436     DOI: 10.1177/0148607199023005243

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  10 in total

1.  Glutamine: a life-threatening deficiency in the critically ill?

Authors:  R D Griffiths; F Andrews
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

2.  Effects of glutamine on gastrointestinal motor activity in patients following gastric surgery.

Authors:  Erito Mochiki; Tetsuro Ohno; Mitsuhiro Yanai; Yoshitaka Toyomasu; Hiroyuki Andoh; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  Effect of intravenous amino acids on glutamine and protein kinetics in low-birth-weight preterm infants during the immediate neonatal period.

Authors:  Mark M Kadrofske; Prabhu S Parimi; Lourdes L Gruca; Satish C Kalhan
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-01       Impact factor: 4.310

4.  Serum Amino Acids (Glutamine, Glutamate, Methionine, and Arginine) Flux after Cutaneous Thermal and Smoke Inhalation injuries in rats.

Authors:  Y-W Tang
Journal:  Ann Burns Fire Disasters       Date:  2005-12-31

5.  Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients.

Authors:  Inga Tjäder; Olav Rooyackers; Ann-Marie Forsberg; Rokhsareh F Vesali; Peter J Garlick; Jan Wernerman
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

6.  Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial.

Authors:  Ruqaiya M Al Balushi; Jennifer D Paratz; Jeremy Cohen; Merrilyn Banks; Joel Dulhunty; Jason A Roberts; Jeffrey Lipman
Journal:  BMJ Open       Date:  2011-11-14       Impact factor: 2.692

Review 7.  Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID‑19 (Review).

Authors:  José João Name; Andrea Rodrigues Vasconcelos; Ana Carolina Remondi Souza; Wagner José Fávaro
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

8.  Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy.

Authors:  P Rocheteau; L Chatre; D Briand; M Mebarki; G Jouvion; J Bardon; C Crochemore; P Serrani; P P Lecci; M Latil; B Matot; P G Carlier; N Latronico; C Huchet; A Lafoux; T Sharshar; M Ricchetti; F Chrétien
Journal:  Nat Commun       Date:  2015-12-15       Impact factor: 14.919

9.  Prolonged continuous intravenous infusion of the dipeptide L-alanine- L-glutamine significantly increases plasma glutamine and alanine without elevating brain glutamate in patients with severe traumatic brain injury.

Authors:  Mirjam Nägeli; Mario Fasshauer; Jutta Sommerfeld; Angela Fendel; Giovanna Brandi; John F Stover
Journal:  Crit Care       Date:  2014-07-02       Impact factor: 9.097

Review 10.  Glutamine: an obligatory parenteral nutrition substrate in critical care therapy.

Authors:  Peter Stehle; Katharina S Kuhn
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.